Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area

Last updated: June 17, 2026
Sponsor: Boston Scientific Corporation
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Endo-SPONGE

Clinical Study ID

NCT07035431
E7212
  • Ages > 18
  • All Genders

Study Summary

This study is intended to evaluate the safety and effectiveness of Sponge-based Endoscopic Vacuum Therapy (EVT) using Endo-SPONGE for the treatment of Anastomotic Leaks (AL) or Hartmann's stump leakages following colorectal surgery in a prospective multi-center study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Confirmed grade B anastomotic leak as per the ISGRC (International Study Group ofRectal Cancer) grading system after colorectal surgery.

  • Subject is eligible for endoscopic intervention.

  • Subject has a transmural defect of at least 2 cm in diameter following colorectalsurgery in the lower pelvic area.

  • Subject has an anastomotic or Hartmann's stump leak located within anextraperitoneal cavity.

  • Subject has pre-existing diverting ostomy or an ostomy created prior to the firstEndo-SPONGE placement.

  • Subject understands the trial requirements and is willing and able to comply withthe study procedures, all protocol-required follow up evaluations and providewritten informed consent to participate in the study.

  • Investigator decision that EVT is the most suitable treatment of the availabletreatment options.

Exclusion

Exclusion Criteria:

  • Subject is under 18 years of age.

  • Potentially vulnerable subject, including, but not limited to pregnant women.

  • Subject has undergone EVT or other similar interventions for the current colorectalindication.

  • Subject had colorectal surgery more than 60 days prior to the planned studyprocedure.

  • Subject has any necrotic tissue that would require endoscopic debridement prior toEndo-SPONGE placement.

  • Subject has known contraindication for EVT as per the IB.

  • Subject is currently enrolled in another investigational study that would directlyinterfere with the current study, without prior written approval from the sponsor.

Study Design

Total Participants: 66
Treatment Group(s): 1
Primary Treatment: Endo-SPONGE
Phase:
Study Start date:
July 01, 2026
Estimated Completion Date:
December 31, 2028

Connect with a study center

  • Orlando Regional Medical Center

    Orlando, Florida 32806
    United States

    Site Not Available

  • Cleveland Clinic Florida

    Weston, Florida 33331
    United States

    Site Not Available

  • Lahey Medical Center

    Burlington, Massachusetts 01805
    United States

    Site Not Available

  • Mount Sinai

    New York, New York 10029
    United States

    Active - Recruiting

  • Mount Sinai

    New York 5128581, New York 5128638 10029
    United States

    Site Not Available

  • Cleveland Clinic Foundation

    Cleveland, Ohio 44195
    United States

    Site Not Available

  • Penn State Health

    Hershey, Pennsylvania 17033
    United States

    Site Not Available

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania 19107
    United States

    Site Not Available

  • University of Washington Medical Center

    Seattle, Washington 98195
    United States

    Active - Recruiting

  • Marshall University Medical Center

    Huntington, West Virginia 25701
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.